



# MINNESOTA BOARD OF PHARMACY

## **Report to the Legislature on Changes the Board Proposes to Make to the Controlled Substance Schedules Maintained by the Board in Minnesota Rules. (In compliance with Minnesota Statutes Section 152.02, Subd. 12)**

*Jill Phillips, MPH, RPh*

*Executive Director  
Minnesota Board of  
Pharmacy*

*335 Randolph Ave, Suite  
230  
St. Paul, MN 55102*

*(651)201-2825*

*jill.phillips@state.mn.us*

**December 13, 2023**

## **COST OF REPORT**

[Minnesota Statutes §3.197](#) states that a “report to the legislature must contain, at the beginning of the report, the cost of preparing the report, including any costs incurred by another agency or another level of government”. The estimated cost of preparing this report was **\$50.00**. That is the approximate value, in terms of salary and benefits, of the time that Board staff spent preparing the report.

*(The rest of this page is intentionally blank).*

## **Introduction**

The Board of Pharmacy (Board) is submitting this report to the Legislature in compliance with Minnesota Statutes §152.02, subdivision 12. That section states, in part:

“The state Board of Pharmacy shall annually submit a report to the legislature on or before December 1 that specifies what changes the board made to the controlled substance schedules maintained by the board in Minnesota Rules, parts 6800.4210 to 6800.4250, in the preceding 12 months. The report must also specify any orders issued by the board under this subdivision. The report must include specific recommendations for amending the controlled substance schedules contained in subdivisions 2 to 6, so that they conform with the controlled substance schedules maintained by the board in Minnesota Rules, parts 6800.4210 to 6800.4250, and with the federal schedules.”

The Board reviewed and approved this report at its December 13, 2023 meeting.

## **2023 Scheduling Changes**

The Board did not engage in rule-making to make any changes to the controlled substance schedules found in Minnesota Rules Chapter 6800 during calendar year 2023. Nor did it issue any scheduling orders in 2023.

The Board has received reports from law enforcement officials about a few unscheduled synthetic fentanyl, hallucinogens and stimulants that appear to be available for purchase on the streets or from Internet suppliers. In addition, law enforcement officials and healthcare providers have previously expressed concern to the Board related to the abuse of gabapentin – a drug approved by the United States Food and Drug Administration that acts on the same receptor system that benzodiazepines (Valium-like drugs). Consequently, the Board may propose controlled substance scheduling legislation during the 2024 Session.